Show simple item record

dc.contributor.authorWennerberg, E
dc.contributor.authorLhuillier, C
dc.contributor.authorRybstein, MD
dc.contributor.authorDannenberg, K
dc.contributor.authorRudqvist, N-P
dc.contributor.authorKoelwyn, GJ
dc.contributor.authorJones, LW
dc.contributor.authorDemaria, S
dc.date.accessioned2020-08-27T13:09:25Z
dc.date.issued2020-01-28
dc.identifier.citationOncotarget, 2020, 11 (4), pp. 452 - 461
dc.identifier.issn1949-2553
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4043
dc.identifier.eissn1949-2553
dc.identifier.doi10.18632/oncotarget.27464
dc.description.abstractExercise is associated with favorable changes in circulating immune cells and improved survival in early-stage breast cancer patients, but the mechansims remain to be fully elucidated. Preclinical studies indicate that physical activity started before tumor injection reduces tumor incidence and progression. Here we tested whether exercise has anti-tumor effects in mice with established 4T1 mammary carcinoma, a mouse model of triple negative breast cancer. Exercise slowed tumor progression and reduced the tumor-induced accumulation of myeloid-derived suppressor cells (MDSCs). The reduction in MDSCs was accompanied by a relative increase in natural killer and CD8 T cell activation, suggesting that exercise restores a favorable immune environment. Consistently, exercise improved responses to a combination of programmed cell death protein 1 (PD-1) blockade and focal radiotherapy. These data support further investigations of exercise in breast cancer patients treated with combinations of immunotherapy and cytotoxic agents to improve cancer outcomes.
dc.formatElectronic-eCollection
dc.format.extent452 - 461
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleExercise reduces immune suppression and breast cancer progression in a preclinical model.
dc.typeJournal Article
dcterms.dateAccepted2020-01-13
rioxxterms.versionofrecord10.18632/oncotarget.27464
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-01-28
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOncotarget
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiation-enhanced Immunotherapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radiation-enhanced Immunotherapy
pubs.publication-statusPublished
pubs.volume11
pubs.embargo.termsNot known
icr.researchteamRadiation-enhanced Immunotherapyen_US
dc.contributor.icrauthorWennerberg, Eriken


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0